Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIA Study: Endocrine Therapy Plus CDK 4/6 Inhibition in First- or Second-line for HR+ Advanced Breast Cancer
NCT03425838Phase 3Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Nov 2017
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Progression-Free Survival after two lines up to 60 months. Started Nov 2017; status: active, not recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03425838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425838.